```html

Zoster‑Related Urinary Retention

What is Zoster urinary retention?

Urinary retention is the inability to completely empty the bladder. When it occurs in the setting of a herpes zoster (shingles) infection, it is called zoster urinary retention. Shingles is caused by reactivation of the varicella‑zoster virus (VZV), the same virus that produces chickenpox. The virus can affect the sensory and motor nerves that control the bladder, leading to a sudden or gradual loss of bladder contractility. This type of neurogenic urinary retention is most common in older adults, immunocompromised patients, and those with shingles that involve the dermatomes of the torso (especially T10‑L2) or the sacral region (S2‑S4).

Because the bladder is a hollow, muscular organ that relies on a coordinated neural network, any disruption to that network can cause the bladder to become over‑distended, painful, and prone to infection. Prompt recognition and treatment are essential to prevent permanent bladder damage or life‑threatening complications.

Common Causes

Urinary retention can be triggered by many conditions. When it accompanies shingles, the underlying mechanisms are usually neurogenic, but other co‑existing factors often worsen the problem.

• Herpes zoster involving sacral dermatomes (S2‑S4): Direct viral inflammation of the sacral plexus.
• Herpes zoster affecting thoracolumbar dermatomes (T10‑L2): Disruption of the spinal cord pathways that modulate bladder reflexes.
• Post‑herpetic neuralgia (PHN): Persistent pain can lead to reflex inhibition of bladder emptying.
• Spinal cord compression or myelitis: VZV can cause inflammation of the spinal cord itself.
• Medications used to treat shingles: Opioids, antihistamines, and anticholinergics may impair detrusor muscle contraction.
• Age‑related bladder dysfunction: Age‑related loss of smooth‑muscle tone makes the bladder more vulnerable to neurogenic insults.
• Diabetes mellitus: Diabetic autonomic neuropathy can coexist and compound bladder emptying problems.
• Pelvic surgery or radiation: Scarring can affect the nerves that share pathways with the sacral roots.
• Severe constipation or fecal impaction: Large stool burden can mechanically compress the bladder neck.
• Immunosuppression (e.g., HIV, chemotherapy, steroids): Increases the risk of extensive VZV reactivation and nerve damage.

Associated Symptoms

Patients with zoster urinary retention often notice a constellation of other signs that point to a neurogenic process:

• Sharp, burning or vesicular rash that follows a dermatome, most commonly on the flank, abdomen, or buttocks.
• Pain or tingling (paresthesia) in the same area before the rash appears (prodrome).
• Difficulty initiating urination (hesitancy) or a weak urine stream.
• A feeling of incomplete emptying after voiding.
• Abdominal distension or suprapubic pain caused by a full bladder.
• Urinary frequency or urgency that paradoxically coexists with retention.
• Fever, chills, or malaise – especially if a secondary urinary tract infection (UTI) develops.
• Post‑herpetic neuralgia persisting for weeks to months after the rash resolves.

When to See a Doctor

While mild hesitancy may resolve on its own, certain features demand prompt medical evaluation:

• Inability to pass any urine for more than 6–8 hours.
• Severe suprapubic pain or a rapidly enlarging bladder on exam.
• Fever ≥ 38 °C (100.4 °F) with chills, suggesting a secondary infection.
• New or worsening rash involving the genital or perianal area.
• History of diabetes, spinal cord disease, or immunosuppression.
• Recurrent episodes of urinary retention or persistent retention beyond 24 hours.

Early evaluation reduces the risk of bladder over‑distention, renal impairment, and permanent nerve injury.

Diagnosis

Diagnosis combines a careful history, focused physical examination, and targeted investigations.

History & Physical Exam

• Document the onset, distribution, and duration of the vesicular rash.
• Ask about urinary patterns: frequency, hesitancy, dribbling, nocturia.
• Assess for systemic symptoms (fever, malaise) and risk factors (age, immunosuppression, recent surgery).
• Perform a focused neurological exam of the lower abdomen, perineum, and lower extremities.
• Palpate the bladder; a palpable suprapubic mass suggests retention.

Laboratory & Imaging Studies

• Post‑void residual (PVR) volume: Measured by bedside bladder ultrasound or catheterization. A PVR >150 mL is diagnostic of retention.
• Urinalysis & urine culture: To rule out UTI, which frequently co‑exists.
• Blood tests: CBC, CRP, and renal function (BUN/creatinine) to assess infection and kidney impact.
• Magnetic resonance imaging (MRI) of the spine: Indicated if there is suspicion of spinal cord involvement, myelitis, or compression.
• Electromyography (EMG) or urodynamic studies: In chronic cases, these evaluate detrusor muscle activity and sphincter coordination.

Diagnostic Criteria (simplified)

1. Documented acute herpes zoster rash in a relevant dermatome.
2. Objective evidence of urinary retention (PVR >150 mL or inability to void).
3. Exclusion of mechanical obstruction (e.g., prostate enlargement) by imaging or physical exam.

Treatment Options

Treatment aims to relieve the viral infection, restore bladder emptying, and prevent complications.

Antiviral Therapy

• Acyclovir 800 mg five times daily, famciclovir 500 mg three times daily, or valacyclovir 1 g three times daily for 7–10 days.
• Start within 72 hours of rash onset for maximal efficacy (reduces nerve inflammation and duration of urinary symptoms).<sup>1</sup>

Pain Management

• Gabapentin or pregabalin for neuropathic pain (300‑600 mg/day titrated).
• Short‑course oral steroids (e.g., prednisone 60 mg daily taper) may reduce inflammation, but weigh infection risk.
• Topical lidocaine or capsaicin “patches” for localized pain.

Bladder Decompression

• Intermittent catheterization: Self‑catheterize every 4–6 hours until normal voiding returns.
• Indwelling Foley catheter: Used only briefly (≤48 h) to avoid infection.
• Monitor urine output and maintain sterile technique to prevent catheter‑associated UTI.

Pharmacologic Support for Bladder Function

• Alpha‑blockers (tamsulosin 0.4 mg daily): Helpful in males with concomitant prostatic outflow obstruction.
• Cholinergic agents (bethanechol 25 mg PO q.i.d.): May stimulate detrusor contraction, but use cautiously due to side‑effects.

Physical Therapy & Pelvic Floor Rehabilitation

• Pelvic floor muscle training can improve coordination once the acute phase resolves.
• Bladder‑training schedules (timed voiding every 2–3 hours) help re‑establish normal storage‑voiding cycles.

Management of Complications

• UTI: Treat with culture‑directed antibiotics (e.g., nitrofurantoin, trimethoprim‑sulfamethoxazole).
• Hydronephrosis or renal dysfunction: Requires urology referral for possible nephrostomy or surgical decompression.

Follow‑up Care

Most patients improve within 2–4 weeks. Schedule a follow‑up appointment to:

• Re‑measure post‑void residual volumes.
• Assess for lingering pain (post‑herpetic neuralgia).
• Evaluate renal function if retention was prolonged.

Prevention Tips

Because shingles is the root cause, preventing reactivation is the most effective strategy.

• Shingles vaccine (Shingrix): Recombinant zoster vaccine recommended for adults ≥50 years or immunocompromised adults ≥19 years. Two doses, 2–6 months apart.<sup>2</sup>
• Maintain good glycemic control if you have diabetes.
• Avoid prolonged high‑dose steroids unless medically necessary.
• Practice good hand hygiene and avoid contact with individuals with active chickenpox or shingles if you are immunocompromised.
• Stay up to date with routine immunizations (influenza, COVID‑19) that can reduce overall immune stress.
• Prompt treatment of a herpes zoster rash (see antiviral section) reduces neural damage and urinary complications.
• Regular pelvic floor exercises and bladder‑health habits (adequate fluid intake, timed voiding) help maintain normal bladder function.

Emergency Warning Signs

References

1. Mayo Clinic. “Shingles (herpes zoster).” Updated 2023. https://www.mayoclinic.org/diseases-conditions/shingles/symptoms-causes/syc-20373057
2. CDC. “Shingles (Herpes Zoster) Vaccine (Shingrix) Recommendations.” 2024. https://www.cdc.gov/vaccines/vpd/shingles/public/index.html
3. National Institute of Diabetes and Digestive and Kidney Diseases. “Urinary Retention.” 2022. https://www.niddk.nih.gov/health-information/urologic-diseases/urinary-retention
4. Cleveland Clinic. “Neurogenic Bladder.” 2023. https://my.clevelandclinic.org/health/diseases/17200-neurogenic-bladder
5. World Health Organization. “Varicella‑zoster virus infections.” 2021. https://www.who.int/news-room/fact-sheets/detail/varicella-zoster-virus-infections
6. JAMA Network. “Antiviral Therapy for Herpes Zoster Reduces Complications.” 2022;327(7): 652‑660.

```